We would like to thank Tanriverdi and Kaskari for their interest in our study regarding the frequency of fibromyalgia syndrome in breast cancer patients which was accepted for publication in International Journal of Clinical Oncology. We think that the letter of Tanriverdi and Kaskari consists of the subjects which we mentioned in our manuscript as discussion, limitations or suggestions for future studies. The first issue raised by Tanriverdi and Kaskari was the missing ‘‘adjuvant’’ terminology in our study. Tanriverdi and Kaskari said that, as they know, in postmenopausal women, aromatase inhibitors (AIs) cause musculoskeletal menopausal symptoms by further lowering the estrogen level; and in previous studies, when Tmx and placebo were compared with AIs, the women using AIs had more musculoskeletal side effects, and arthralgia and myalgia were the most common musculoskeletal side effects reported [1]. Tanriverdi and Kaskari suggested that, therefore, in the study’s design the study group was statistically poor, the frequency of fibromyalgia syndrome (FM) was analyzed and in fact this situation removed the study from the topic it described. Rheumatologic symptoms and FM cases have been reported as a result of adjuvant treatments or chemotherapy used in breast cancer, as we mentioned in our study [2]. The history of chemotherapy, hormonotherapy or radiotherapy in our patients was explained in the results section of our manuscript. The main topic of our study was to explore whether the frequency of FM after mastectomy depended on adjuvant therapy or not. In any case the authors overlooked that the main question of our study was not to investigate the effect of adjuvant therapy after mastectomy for the development of FM. The aim of our manuscript was not to investigate the reasons for widespread pain or fibromyalgia in breast cancer patients. We do not agree with the authors for this comment because we explained the aims of our study previously. The second issue raised by Tanriverdi and Kaskari was that if the study’s title was ‘‘The effect of regional and widespread pain on the quality of life in breast cancer patients’’ perhaps it could reflect the complete article. The first aim of the study was to determine the frequency of FM in breast cancer patients after mastectomy, and the second aim of the study was to explore the relationships between FM, fatigue severity, and quality of life. We do not agree that the suggested title of ‘‘The effect of regional and widespread pain on the quality of life in breast cancer patients’’ could reflect complete article, since the suggested title does not consist of the term ‘‘fibromyalgia,’’ which is the main topic of our study. We would like to bring to light first the definitions of widespread pain and fibromyalgia, and the differences of these disorders. Fibromyalgia is a chronic widespread pain disorder characterized by sleep disorders, fatigue, psychiatric illnesses (depression, anxiety), and somatic disorders (irritabl bowel syndome, headache, fatigue, paresthesia on extremities). FM diagnosis is based on two criteria established by the American College of Rheumatology (ACR): one of which is a history of widespread pain lasting more than 3 months, and the This reply refers to the comment available at doi:10.1007/s10147-013-0545-6.